Evidence map›Paper›PMID 27042842›Full record

ArticleBone marrow transplantation2016

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).

A Stamatoullas, P Brice, M S Gueye, S Mareschal, P Chevallier, R Bouabdallah, S Nguyenquoc, S Francois, P Turlure, P Ceballos and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Current Treatment Options for Older Patients with Hodgkin Lymphoma.Current treatment options in oncology · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

A StamatoullasCentre Henri Becquerel, Rouen, France.
P BriceDepartment of Hematology-Oncology, Hospital Saint Louis, Paris, France.
M S GueyeSFGM-TC, Paris, France.
S MareschalCentre Henri Becquerel, Rouen, France.
P ChevallierDepartment of Clinical Hematology, Nantes University Hospital, Nantes, France.
R BouabdallahInstitut Paoli-Calmettes, Marseille, France.
S NguyenquocDepartment of Hematology, Hopital Pitie-Salpetriere, Paris, France.
S FrancoisHematology CHU Angers, Angers, France.
P TurlureCHU Dupuytren, Université Limoges, Limoges, France.
P CeballosHôpital Lapeyronie, Montpellier, France.
H MonjanelService d'Hématologie et Thérapie Cellulaire, CHRU de Tours, Tours, France.
J-H BourhisDivision of Hematology, Institut Gustave Roussy, Villejuif, France.
G GuillermDepartment of Hematology, Hôpital Augustin Morvan, Brest, France.
M MohtyDepartment of Clinical Hematology, Hôpital Saint-Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire, APHP, Paris, France.
P BironDepartment of Onco-Hematology, Centre Léon Berard, Lyon, France.
J CornillonDepartment of Hematology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France.
K BelhadjLymphoid Malignancies Unit, Hôpital Henri Mondor and Université Paris, Creteil, France.
C BonmatiHôpital de Brabois, Vandoeuvre les Nancy, France.
M-S DilhuydyDepartment of Hematology, Hopital Haut-Leveque, Pessac, France.
A HuynhDepartment of Hematology, University Hospital of Toulouse, Toulouse, France.
M BernardCHRU Rennes, Rennes, France.
M-L ChrétienDepartment of Hematology, Dijon University Hospital, Dijon, France.
R Peffault de LatourDepartment of Hematology-Bone Marrow Transplantation, Saint Louis Hospital, Paris, France.
H TillyCentre Henri Becquerel, Rouen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1-2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III-IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.

Indexed as

AgedAge FactorsAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansMaleMiddle AgedRetrospective StudiesSalvage TherapySurvival AnalysisTransplantation, Autologous

Identifiers

PMID27042842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.